adefovir dipivoxil + nelfinavir

Adefovir dipivoxil + nelfinavir is an antiretroviral combination consisting of two small-molecule drugs used in the management of human immunodeficiency virus type 1 (HIV-1) infection as part of combination antiretroviral therapy (ART). **Adefovir dipivoxil** is a nucleotide analog reverse transcriptase inhibitor (NtRTI) that inhibits HIV reverse transcriptase by competing with natural deoxyadenosine triphosphate, leading to premature termination of viral DNA synthesis. **Nelfinavir** is a protease inhibitor (PI) that blocks the HIV-1 protease enzyme, essential for the cleavage of viral polyprotein precursors into functional proteins, thereby preventing maturation of infectious virions. This combination has been studied in patients with virological failure to prior ART regimens, and while adefovir has shown some in vitro synergy with nelfinavir, real-world efficacy and safety profiles (notably nephrotoxicity with adefovir) have limited the widespread clinical use of this regimen[1][2][4].